ICCC — ImmuCell Corporation

ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: Achieved a record $10.4 million in product sales, a 28.4% increase year-over-year.
• Gross Margin: Improved to 45% from 41.6% in Q1 2025, despite a 2.4% reduction due to legacy Re-Tain costs.
• Net Income: Increased by 34% to $1.9 million ($0.21 per share) compared to $1.4 million ($0.16 per share) in Q1 2025.
• EBITDA: Rose to $2.6 million from $2.3 million year-over-year.
• Cash Position: Ended the quarter with $6.8 million in cash and $8.7 million in inventory. Working capital increased to $15 million from $13 million at the end of 2025.

2. Strategic Updates and Business Highlights:

• Focused on the calf scours market, particularly the First Defense product line, which is seeing significant growth.
• Strong sales performance of Tri-Shield, the flagship product, which grew 38.5% year-over-year.
• The company is expanding its manufacturing capacity, achieving over 450,000 units per month, up from 380,000 in 2025.
• A $2 million settlement with a former contract manufacturer will be used to enhance capacity.
• Expanded the sales force and territories, now covering the entire U.S. market for both dairy and beef calves.

3. Forward Guidance and Outlook:

• The company is optimistic about continued growth in the calf scours prevention market, with an estimated addressable market exceeding $200 million in the U.S. and potentially five times larger internationally.
• Plans to enhance manufacturing capabilities and product availability to meet increasing demand.
• Ongoing investments in leadership and strategic international business development are expected to support long-term growth.

4. Bad News, Challenges, or Points of Concern:

• International sales declined 30.2% to approximately $600,000, indicating potential challenges in global market penetration.
• Operating expenses rose to $2.7 million from $2.2 million, driven by increased G&A and sales expenses.
• The company faces ongoing challenges related to manufacturing capacity and contamination risk, which require continuous management and improvement.

5. Notable Q&A Insights:

• Management emphasized the importance of improving production planning and reducing waste to enhance yield.
• The introduction of a bulk First Defense product is aimed at operations that prefer group feeding, which may compete with existing products.
• The sales strategy is focused on increasing customer contact to drive revenue, with a significant emphasis on educating customers about product differentiation.
• Management acknowledged the need for disciplined market prioritization for international expansion, highlighting the complexity of entering new markets.

Overall, ImmuCell's Q1 2026 results reflect strong growth and strategic focus on its core products, despite facing some challenges in international sales and operational expenses. The company is well-positioned for future growth with its ongoing investments and market strategies.